Gentian to divest PreTect AS to Mel-Mont Medical, Inc
Gross proceeds of transaction is estimated to 7.7 MNOK
PreTect had revenue of 2.6 MNOK and EBITDA of -1.8 MNOK per September 30th 2020
Financial gain of 4.5 MNOK from transaction to be booked in Q4 2020
05 Nov 2020
Divestment of PreTect AS
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Divestment of PreTect AS
Gentian Diagnostics ASA (GENT:OSL) | 0 0 0.0%
- Published:
05 Nov 2020 -
Author:
Lars Mørland Knudsen -
Pages:
6
Gentian to divest PreTect AS to Mel-Mont Medical, Inc
Gross proceeds of transaction is estimated to 7.7 MNOK
PreTect had revenue of 2.6 MNOK and EBITDA of -1.8 MNOK per September 30th 2020
Financial gain of 4.5 MNOK from transaction to be booked in Q4 2020